Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis.
Int J Immunopathol Pharmacol
; 35: 20587384211059675, 2021.
Article
in English
| MEDLINE | ID: covidwho-1582485
ABSTRACT
INTRODUCTION:
The fully-human monoclonal anti-interleukin (IL)-1ß antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to acute respiratory distress syndrome.OBJECTIVES:
The goal of our retrospective, observational analysis was to evaluate the safety and efficacy of subcutaneous (s.c.) canakinumab in combination with our standard of care (SOC) treatment of selected patients with COVID-19 with respiratory failure and elevated reactive pro-inflammatory markers.METHODS:
Eight participants received two doses of s.c. canakinumab 150 mg (or 2 mg/kg for participants weighing ≤40 kg) in addition to SOC. 12 patients received only SOC treatment.RESULTS:
Canakinumab treatment reduced the need for mechanical ventilation and reduced proinflammatory markers, resulting in an amelioration of the final outcome, with respect to the control group who received SOC alone. The treatment was safe and well tolerated; no adverse events were reported.CONCLUSION:
The use of canakinumab (300 mg, s.c.) in the early stage of COVID-19 with mild-to-moderate respiratory failure was superior to SOC at preventing clinical deterioration and may warrant further investigation as a treatment option for patients with COVID-19 who experience a hyperinflammatory response in the early stage of the disease.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiration, Artificial
/
Interleukin-1beta
/
Antibodies, Monoclonal, Humanized
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
English
Journal:
Int J Immunopathol Pharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
/
Pathology
Year:
2021
Document Type:
Article
Affiliation country:
20587384211059675
Similar
MEDLINE
...
LILACS
LIS